A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels.
Bouatia-Naji N,
Rocheleau G,
Van Lommel L,
Lemaire K,
Schuit F,
Cavalcanti-Proença C,
Marchand M,
Hartikainen AL,
Sovio U,
De Graeve F,
Rung J,
Vaxillaire M,
Tichet J,
Marre M,
Balkau B,
Weill J,
Elliott P,
Jarvelin MR,
Meyre D,
Polychronakos C,
Dina C,
Sladek R,
Froguel P.
CNRS UMR 8090 Institute of Biology, Pasteur Institute of Lille and Lille 2 Droit et Santé University, 59019 Lille, France.
Several studies have shown that healthy individuals with fasting plasma glucose (FPG) levels at the high end of the normal range have an increased risk of mortality. To identify genetic determinants that contribute to interindividual variation in FPG, we tested 392,935 single-nucleotide polymorphisms (SNPs) in 654 normoglycemic participants for association with FPG, and we replicated the most strongly associated SNP (rs560887, P = 4 x 10(-7)) in 9353 participants. SNP rs560887 maps to intron 3 of the G6PC2 gene, which encodes glucose-6-phosphatase catalytic subunit-related protein (also known as IGRP), a protein selectively expressed in pancreatic islets. This SNP was associated with FPG (linear regression coefficient beta = -0.06 millimoles per liter per A allele, combined P = 4 x 10(-23)) and with pancreatic beta cell function (Homa-B model, combined P = 3 x 10(-13)) in three populations; however, it was not associated with type 2 diabetes risk. We speculate that G6PC2 regulates FPG by modulating the set point for glucose-stimulated insulin secretion in pancreatic beta cells.
PMID: 18451265 [PubMed - indexed for MEDLINE]